Skip Navigation LinksHome > March 1, 2014 - Volume 65 - Issue 3 > Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HC...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000073
Brief Report: Clinical Science

Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HCV Genotype 1–Infected Subjects With Insulin Resistance and Previous Nonresponse to Peginterferon and Ribavirin Therapy: A5239

Marks, Kristen M. MD, MS*; Kitch, Douglas MS; Chung, Raymond T. MD; Hadigan, Colleen MD, MPH§; Andersen, Janet ScD; Tien, Phyllis MD‖,¶; Luetkemeyer, Annie MD#; Alston-Smith, Beverly MD§; Glesby, Marshall J. MD, PhD*; the A5239 Team

Collapse Box


Abstract: Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment. In this multicenter, single-arm pilot study, adult, HIV/HCV genotype 1–coinfected previous nonresponders to peginterferon/ribavirin (PegIFN/RBV) with homeostatic model assessment of insulin resistance >2.5 were treated with pioglitazone (PIO) for 24 weeks followed by PegIFN/RBV/PIO. Three of 19 subjects (15.8%) achieved undetectable HCV RNA at week 24 of PegIFN/RBV/PIO, which was not significantly different than the historical null rate of 10% (P = 0.29, lower limit of the exact 1-sided 90% confidence interval 5.9%). Over the 24 weeks of PIO monotherapy, alanine aminotransferase and aspartate aminotransferase declined significantly and correlated with improved metabolic parameters.

© 2014 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.